RxDoctor Payments Data

Philbert Ford, MD

Infectious Disease · Tallahassee, FLNPI 1891711776

Payments from drug & device makers

$11,540in general payments, 2019–2025

Across 167 payments — averaging $69.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$10K
  • Shionogi Inc$394
  • AbbVie$358
  • Merck$328
  • Gilead$287
  • Johnson & Johnson$239
  • plus $356 from 5 others

What the payments were for

  • Consulting fees$7,82068%
  • Travel & lodging$4104%
  • Food & beverage$2,98226%
  • Education$3273%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,540 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$68,172
Medicare patients
149
Services billed
16,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala386$1,595,805
TriumeqAbacavir/Dolutegravir/Lamivudi283$1,062,128
CabenuvaCabotegravir/Rilpivirine75$506,411
DovatoDolutegravir Sodium/Lamivudine153$435,519
OdefseyEmtricitab/Rilpiviri/Tenof Ala102$369,404
TivicayDolutegravir Sodium122$287,678
JulucaDolutegravir/Rilpivirine70$261,652
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$237,399
GenvoyaElviteg/Cob/Emtri/Tenof Alafen56$228,048
RukobiaFostemsavir Tromethamine17$153,490
DescovyEmtricitabine/Tenofov Alafenam59$132,494
IsentressRaltegravir Potassium58$114,807
Darunavir79$72,055
DelstrigoDoravirine/Lamivu/Tenofov Diso19$47,726
Daptomycin50$32,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Cabenuva, Dovato, Tivicay, Juluca$9,578$2,706,878720 claims
GileadBiktarvy, Genvoya, Descovy$287$1,956,347501 claims
MerckIsentress, Delstrigo$328$162,53377 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →